Telix Pharmaceuticals Ltd (TLX.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2021 | 03-2021 | 12-2020 | 09-2020 | 06-2020 | |
| Cash Flows From Operating Activities | |||||
| Operating Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Investing Activities | |||||
| Net Acquisitions | N/A | N/A | -246 | N/A | N/A |
| Purchase Sale Intangibles | -2 | N/A | -28 | -26 | N/A |
| Other Investing Activity | -104 | -30 | -22 | 0 | 34 |
| Investing Cash Flow | $-106 | $-30 | $-296 | $-26 | $34 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 111 |
| Debt Repayment | -34 | -43 | 523 | -36 | -109 |
| Common Stock Issued | 160 | 485 | 27,152 | 121 | 192 |
| Other Financing Activity | -215 | -219 | -274 | -207 | -300 |
| Financing Cash Flow | $-89 | $224 | $27,401 | $-121 | $-105 |
| Exchange Rate Effect | 945 | 271 | -2,425 | -469 | -2,135 |
| Beginning Cash Position | 46,148 | 59,301 | 19,760 | 17,414 | 23,699 |
| End Cash Position | 37,278 | 46,730 | 60,808 | 18,359 | 16,751 |
| Net Cash Flow | $-9,815 | $-12,842 | $43,473 | $1,414 | $-4,814 |
| Free Cash Flow | |||||
| Capital Expenditure | -2 | N/A | -28 | -26 | N/A |
| Free Cash Flow | -2 | 0 | -28 | -26 | 0 |